ACDF Brief comments: The evolving role of SGLT2 inhibitors in heart failure?

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

ACDF Brief comments: What has changed significantly in evaluating and considering CV risk in managing patients with diabetes?1
ACDF Brief comments: What has changed significantly in evaluating and considering CV risk in managing patients with diabetes?1
Asian Cardio Diabetes Forum 2019
ACDF Brief comments: What has changed significantly in evaluating and considering CV risk in managing patients with diabetes?1
- Prof John E Deanfield
ACDF Brief comments: Key challenges in reinforcing CV risk management among diabetic patients
ACDF Brief comments: Key challenges in reinforcing CV risk management among diabetic patients
Asian Cardio Diabetes Forum 2019
ACDF Brief comments: Key challenges in reinforcing CV risk management among diabetic patients
- Prof John E Deanfield
Lecture: SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits?
Lecture: SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits?
Asian Cardio Diabetes Forum 2019
Lecture: SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits?
- Prof. Nikolaus Marx, MD
Lecture: Heart Failure: The next frontier for SGLT2 inhibitors?
Lecture: Heart Failure: The next frontier for SGLT2 inhibitors?
Asian Cardio Diabetes Forum 2019
Lecture: Heart Failure: The next frontier for SGLT2 inhibitors?
- Prof. Nikolaus Marx, MD